Melasma
☆ Yng nghanlyniadau Stiftung Warentest 2022 o’r Almaen, roedd boddhad defnyddwyr â ModelDerm ond ychydig yn is nag ymgynghoriadau telefeddygaeth taledig.
Mae'n gyflwr cyffredin a welwyd mewn merched Asiaidd yn eu 40au cynnar. Mae'r briw â chylch yn y llun yn agosach at lentigo yn hytrach na melasma.
References
Tranexamic acid is a novel treatment option for melasma; however, there is no consensus on its use. This systematic review searched major databases for relevant publications to March 2016. Eleven studies with 667 participants were included. Pooled data from tranexamic acid-only observational studies with pre- and post-treatment Melasma Area and Severity Index (MASI) showed a decrease of 1.60 in MASI after treat?ment with tranexamic acid. The addition of tranexamic acid to routine treatment modalities resulted in a further decrease in MASI of 0.94. These results support the efficacy and safety of tranexamic acid, either alone or as an adjuvant to routine treatment modalities for melasma.
Yn ddiweddar, mae laser low-fluence Q-switched Nd:YAG (LFQSNY) wedi dod yn boblogaidd ar gyfer trin melasma, yn enwedig yn Asia. Roedd crynhoi astudiaethau amrywiol yn heriol, ond mae LFQSNY yn ymddangos yn gyffredinol effeithiol a diogel ar gyfer melasma o'i gymharu â therapïau traddodiadol. Fodd bynnag, mae rhai achosion o hypopigmentation brith wedi'u nodi fel sgîl-effaith LFQSNY, o bosibl oherwydd ynni laser uchel. Gall defnydd ymosodol o LFQSNY hefyd arwain at hyperpigmentation o lid, yn enwedig mewn arlliwiau croen tywyllach.
Recently, the low-fluence Q-switched Nd:YAG laser (LFQSNY) has been widely used for treating melasma, especially in Asia. It was hard to summarize the heterogenous studies, but LFQSNY appeared to be a generally effective and safe treatment for melasma considering the results of previous conventional therapies. However, mottled hypopigmentation has been occasionally reported to develop and persist as an adverse event of LFQSNY, which may be associated with the high accumulated laser energy. When used aggressively, even LFQSNY can induce hyperpigmentation via unwanted inflammation, especially in darker skin.
Recently, the low-fluence Q-switched Nd:YAG laser (LFQSNY) has been widely used for treating melasma, especially in Asia. It was hard to summarize the heterogenous studies, but LFQSNY appeared to be a generally effective and safe treatment for melasma considering the results of previous conventional therapies. However, mottled hypopigmentation has been occasionally reported to develop and persist as an adverse event of LFQSNY, which may be associated with the high accumulated laser energy. When used aggressively, even LFQSNY can induce hyperpigmentation via unwanted inflammation, especially in darker skin.
Mae problemau pigmentiad i'w cael yn aml mewn gofal sylfaenol. Mae mathau cyffredin o anhwylderau hyperpigmentation yn cynnwys post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
Pigmentation problems are often found in primary care. Common types of hyperpigmentation disorders include post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
Pigmentation problems are often found in primary care. Common types of hyperpigmentation disorders include post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
Ni ellir datrys melasma gyda thriniaeth laser am gyfnod penodol o amser, gan ei fod yn glefyd lle mae pigment yn cael ei gynhyrchu'n barhaus. Mae asid trancsenemig yn helpu i wella i leihau'r pigmentiad.
○ triniaeth
Mewn rhai gwledydd (e.e. Japan, Korea), mae asid tranexamig trwy’r geg ar gael dros y cownter ac mae’n effeithiol. Gall yr hufen melasma gydag asid tranexamig ac asid azelaic fod yn rhannol ddefnyddiol.
Gellir defnyddio hydroquinone yn topig ar gyfer trin hyperbigmentation, ond ataliodd yr FDA y cynhyrchion OTC sy'n cynnwys hydroquinone yn 2020.
#Tranexamic acid [TRANSINO]
#Laser toning technique (low fluence QS1064 laser)
#Triluma